Clinical Trials Directory

Trials / Unknown

UnknownNCT04128137

Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension

Evaluation of Efficacy and Tolerance of Fludrocortisone (Flucortac) in the Treatment of Orthostatic Neurogenic Hypotension

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
90 (estimated)
Sponsor
H.A.C. PHARMA · Industry
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

To evaluate the efficacy of a 4-week fludrocortisone (FLU) treatment on systolic blood pressure depression after 5 minutes of active orthostatism in patients with neurogenic orthostatic hypotension (HON) symptomatic, despite treatment with non-drug measures with or without midodrine.

Detailed description

The objective of the study is to demonstrate the efficacy of FLU on systolic blood pressure depression in patients with neurogenic orthostatic hypotension. The study is randomised versus placebo.Each patient will be followed for a maximum of 5 months, with no more than 8 visits to the investigator (V0 at Day-7, V1 at D0, V2 at D7, V3 at D+14, V4 at D+21, V5 at D+ 28, V6 at D+56 and V7 only for patients on the FLU arm at D+140. The presence of a comparator control group with placebo permits to evaluate the efficacy and the tolerance of FLU independently of the natural evolution of the pathology, in patients benefiting from a non-drug or possibly medicated treatment (midodrine) but insufficient.

Conditions

Interventions

TypeNameDescription
DRUGFludrocortisone50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose
OTHERPlacebo50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose

Timeline

Start date
2020-07-09
Primary completion
2024-06-01
Completion
2024-06-01
First posted
2019-10-16
Last updated
2023-10-02

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04128137. Inclusion in this directory is not an endorsement.